PT Kalbe Farma Tbk.

KLBF

ID1000125107

PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for PT Kalbe Farma Tbk.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,405 IDR

Average target price

1,773 IDR

Spread / Average Target

+26.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PT KALBE FARMA TBK.	-12.73%	4.01B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

End-of-day quote INDONESIA S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1,405 ^IDR	-1.75%		+0.36%	-12.73%

Apr. 01	PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 20	Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy	MT

PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy	Feb. 20	MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-06	CI
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Nomura Adjusts Kalbe Farma’s Price Target to IDR2,500 From IDR2,250, Keeps at Buy	23-01-30	MT
Progen Co. Ltd. announced that it has received IDR 155.72 billion in funding from PT Kalbe Farma Tbk.	23-01-01	CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-30	CI
PT Kalbe Farma Tbk. completed the acquisition of a 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S.	22-10-25	CI
Nomura Adjusts Kalbe Farma's Price Target to 2,250 Rupiahs From 1,905 Rupiahs, Keeps at Buy	22-09-22	MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-28	CI
PT Kalbe Farma Tbk. entered into agreement to acquire 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S.	22-07-24	CI
PT Kalbe Farma Tbk.'s Equity Buyback announced on February 10, 2022, has expired.	22-05-07	CI
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
PT Kalbe Farma Tbk. announces an Equity Buyback for 588,000,000 shares, for IDR 1,000,000 million.	22-02-09	CI
PT Kalbe Farma Tbk. authorizes a Buyback Plan.	22-02-08	CI
Nomura Adjusts Kalbe Farma's Price Target to 1,905 Indonesian Rupiahs From1,550 Indonesian Rupiahs, Keeps at Buy	22-01-11	MT
PT Kalbe Farma Tbk.'s Equity Buyback announced on August 25, 2021, has expired.	21-11-18	CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-24	CI
PT Kalbe Farma Tbk. announces an Equity Buyback for 250,000,000 shares, for IDR 250 million.	21-08-25	CI
PT Kalbe Farma Tbk. authorizes a Buyback Plan.	21-08-19	CI
PT KALBE FARMA TBK : Nomura Adjusts Kalbe Farma's Price Target to 1,550 Indonesian Rupiahs From 1,900 Indonesian Rupiahs, Keeps at Buy	21-08-12	MT
Genexine : South Korea's Genexine signs COVID-19 vaccine candidate manufacturing deal with Hanmi	21-05-17	RE